V
Vazyme Biotech
Biotechnology reagents and materials for life sciences research
About Vazyme Biotech
Vazyme Biotech is a biotechnology company focused on the research, development, and production of functional proteins like enzymes, antigens, and antibodies. Founded in 2012 by Dr. Cao Lin, a former university professor, the company was born from the need for more accessible and affordable research reagents. Dr. Cao, who holds a Ph.D. from Nanjing University and an EMBA from China Europe International Business School, established Vazyme with a group of like-minded colleagues to develop enzyme-based solutions for technical challenges in the field.
The company operates across several business sectors, including life sciences, in vitro diagnostics (IVD), and biopharmaceuticals. Its business model involves the in-house production and sale of core raw materials and finished products. Revenue streams are primarily generated from product sales, such as reagents and kits for research and clinical diagnostics, and to a lesser extent, from contract research services. Vazyme serves a global clientele that includes over 10,000 business customers, such as biopharmaceutical companies, research institutions, and hospitals across more than 60 countries. A significant milestone was achieved on November 15, 2021, when the company was listed on the Shanghai Stock Exchange's STAR Market (Stock Code: 688105).
Vazyme's product portfolio is extensive, featuring over 200 types of genetically engineered recombinant enzymes, more than 1,000 high-performance antigens and antibodies, and over 500 terminal products. In the life sciences domain, it offers a wide range of molecular biology reagents, including products for PCR, qPCR, cloning, and next-generation sequencing (NGS) library preparation. For the in-vitro diagnostics market, the company provides raw materials and develops diagnostic reagents and equipment for conditions like infectious diseases, cardiovascular diseases, and tumors. Notably, during the COVID-19 pandemic, Vazyme developed and supplied billions of nucleic acid detection raw materials and hundreds of millions of antigen and antibody detection reagents.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Dec 2021 | $340M | $340M | Undisclosed | — |
| SERIES COther financing | Dec 2020 | $76M | $303M | Sherpa Venture Partners · China Life Private Equity Investment | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Vazyme Biotech is 32K monthly website visits, up 18.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vazyme Biotech in its local ecosystem
The Vazyme Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Danen Capital
Series A3 investors entered at this stage
- GIGF Xinde Investment
Share Capital
Everest Venture Capital
Series B and later3 investors entered at this stage
China Life Insurance
Sherpa Venture Partners- CIChina Life Private Equity Investment
Other known investors1 additional known investor
Nanjing University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vazyme Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vazyme Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








